I-Mab Gets Orphan Drug Designation for Gastric-Cancer Treatment

 I-Mab said on Thursday that it has been granted an orphan drug designation by the U.S. Food and Drug Administration for its gastric-cancer treatment.

The drug, TJ-CD4B, is a novel Claudin bispecific antibody that treats gastric cancer, gastroesophageal junction cancer and related cancers.

The clinical-stage biopharmaceutical company said the designation would help it expedite its global clinical development and bring to market a novel treatment for the group of cancers.

I-Mab said it is undergoing Phase 1 trials in the U.S. and China in patients with advanced solid tumors stemming from gastric and related cancers.

https://www.marketscreener.com/quote/stock/I-MAB-95388118/news/I-Mab-Gets-Orphan-Drug-Designation-for-Gastric-Cancer-Treatment-39651621/